FGF21 and Mitochondrial myopathy: We have previously described that fasting cytokine FGF21 is a potential biomarker for mitochondrial myopathies (Suomalainen et al, 2011), driven by an upstream regulatory AARE element (Tyynismaa et al, 2010).